Aug 15th 2012 - Edison Investment Research today published a report on Arrowhead Research entitled "Improving Focus". In summary, the report says:
The 2011 acquisition of Roche’s RNAi (RNA interference) business makes Arrowhead one of the leaders in RNAi and delivery solutions for RNAi. The recent acquisition of Alvos Therapeutics adds a library of homing peptides, also aimed at developing targeted therapeutics, with or without the use of RNAi. This will speed up development of new projects both for partnering and in-house development. The most advanced projects in-house are a first-in-class obesity compound and an RNAi compound for solid tumours (both Phase I), valued at $60m. The value of the platform technology is not included in this figure.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »